200 related articles for article (PubMed ID: 6411902)
1. Distribution of valproic acid and its metabolites in various brain areas of dogs and rats after acute and prolonged treatment.
Löscher W; Nau H
J Pharmacol Exp Ther; 1983 Sep; 226(3):845-54. PubMed ID: 6411902
[TBL] [Abstract][Full Text] [Related]
2. Valproic acid in amygdala-kindled rats: alterations in anticonvulsant efficacy, adverse effects and drug and metabolite levels in various brain regions during chronic treatment.
Löscher W; Fisher JE; Nau H; Hönack D
J Pharmacol Exp Ther; 1989 Sep; 250(3):1067-78. PubMed ID: 2506334
[TBL] [Abstract][Full Text] [Related]
3. Comparative transfer of valproic acid and of an active metabolite into brain and liver: possible pharmacological and toxicological consequences.
Löscher W; Nau H
Arch Int Pharmacodyn Ther; 1984 Aug; 270(2):192-202. PubMed ID: 6435554
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the pharmacological and biochemical profiles of valproic acid (VPA) and its cerebral metabolite (2-en-VPA) after oral administration in mice.
Keane PE; Simiand J; Morre M
Methods Find Exp Clin Pharmacol; 1985 Feb; 7(2):83-6. PubMed ID: 2859407
[TBL] [Abstract][Full Text] [Related]
5. Valproic acid: metabolite concentrations in plasma and brain, anticonvulsant activity, and effects on GABA metabolism during subacute treatment in mice.
Löscher W; Nau H
Arch Int Pharmacodyn Ther; 1982 May; 257(1):20-31. PubMed ID: 6810778
[TBL] [Abstract][Full Text] [Related]
6. Transfer of valproic acid and its main active unsaturated metabolite to the gestational tissue: correlation with neural tube defect formation in the mouse.
Nau H
Teratology; 1986 Feb; 33(1):21-7. PubMed ID: 3090732
[TBL] [Abstract][Full Text] [Related]
7. Valproic acid: brain and plasma levels of the drug and its metabolites, anticonvulsant effects and gamma-aminobutyric acid (GABA) metabolism in the mouse.
Nau H; Löscher W
J Pharmacol Exp Ther; 1982 Mar; 220(3):654-9. PubMed ID: 6801254
[TBL] [Abstract][Full Text] [Related]
8. Time course of alpha-fluorinated valproic acid in mouse brain and serum and its effect on synaptosomal gamma-aminobutyric acid levels in comparison to valproic acid.
Tang W; Palaty J; Abbott FS
J Pharmacol Exp Ther; 1997 Sep; 282(3):1163-72. PubMed ID: 9316822
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the effects of valproate and its major active metabolite E-2-en-valproate on single unit activity of substantia nigra pars reticulata neurons in rats.
Rohlfs A; Rundfeldt C; Koch R; Löscher W
J Pharmacol Exp Ther; 1996 Jun; 277(3):1305-14. PubMed ID: 8667191
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of valproic acid and metabolites in mouse plasma and brain following constant-rate application of the drug and its unsaturated metabolite with an osmotic delivery system.
Nau H; Zierer R
Biopharm Drug Dispos; 1982; 3(4):317-28. PubMed ID: 6819013
[TBL] [Abstract][Full Text] [Related]
11. Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats.
Blotnik S; Bergman F; Bialer M
Drug Metab Dispos; 1996 May; 24(5):560-4. PubMed ID: 8723737
[TBL] [Abstract][Full Text] [Related]
12. Comparative pharmacodynamics and brain distribution of E-delta 2-valproate and valproate in rats.
Semmes RL; Shen DD
Epilepsia; 1991; 32(2):232-41. PubMed ID: 2004628
[TBL] [Abstract][Full Text] [Related]
13. Anticonvulsant activity of metabolites of valproic acid.
Löscher W
Arch Int Pharmacodyn Ther; 1981 Jan; 249(1):158-63. PubMed ID: 6784685
[TBL] [Abstract][Full Text] [Related]
14. Bioactivation of a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, via glucuronidation. LC/MS/MS characterization of the GSH-glucuronide diconjugates.
Tang W; Abbott FS
Chem Res Toxicol; 1996 Mar; 9(2):517-26. PubMed ID: 8839057
[TBL] [Abstract][Full Text] [Related]
15. Effect of intracerebroventricular continuous infusion of valproic acid versus single i.p. and i.c.v. injections in the amygdala kindling epilepsy model.
Serralta A; Barcia JA; Ortiz P; Durán C; Hernández ME; Alós M
Epilepsy Res; 2006 Jul; 70(1):15-26. PubMed ID: 16616829
[TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en-valproic acid in different animal models of epilepsy.
Löscher W; Nau H; Marescaux C; Vergnes M
Eur J Pharmacol; 1984 Mar; 99(2-3):211-8. PubMed ID: 6428923
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P-450-mediated dehydrogenation of 2-n-propyl-2(E)-pentenoic acid, a pharmacologically-active metabolite of valproic acid, in rat liver microsomal preparations.
Kassahun K; Baillie TA
Drug Metab Dispos; 1993; 21(2):242-8. PubMed ID: 8097692
[TBL] [Abstract][Full Text] [Related]
18. Increase in antiepileptic efficacy during prolonged treatment with valproic acid: role of inhibition of histone deacetylases?
Hoffmann K; Czapp M; Löscher W
Epilepsy Res; 2008 Oct; 81(2-3):107-13. PubMed ID: 18538545
[TBL] [Abstract][Full Text] [Related]
19. Disposition of valproic acid in the rat: dose-dependent metabolism, distribution, enterohepatic recirculation and choleretic effect.
Dickinson RG; Harland RC; Ilias AM; Rodgers RM; Kaufman SN; Lynn RK; Gerber N
J Pharmacol Exp Ther; 1979 Dec; 211(3):583-95. PubMed ID: 390116
[TBL] [Abstract][Full Text] [Related]
20. Effect of valproic acid on glycine conjugation of benzoic acid.
Gregus Z; Fekete T; Varga F; Klaassen CD
J Pharmacol Exp Ther; 1993 Dec; 267(3):1068-75. PubMed ID: 8263766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
